期刊
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
卷 22, 期 1, 页码 67-72出版社
KARGER
DOI: 10.1159/000093315
关键词
Alzheimer's disease; ESR1 polymorphisms; APOE polymorphism; APOE concentrations
Background: Many studies have shown that estrogen replacement therapy may improve cognitive function in women and reduce the risk of Alzheimer's disease ( AD). Because most of the estrogen neuroprotective effect is mediated by receptors, we studied the associations between estrogen receptor alpha (ESR1) polymorphisms (Pvu II and Xba I) and AD, and their interactions with apolipoprotein E ( APOE) polymorphism and plasma levels. Methods: ESR1 genotypes and APOE plasma concentrations were determined in a sample of AD patients and controls. Results: ESR1 PP and XX genotypes were associated with an increased risk for AD only in males ( OR = 3.6, 95% CI = 1.2 - 10.9) and conferred a relevant additional risk of AD to subjects also carrying APOE e* 4 allele ( OR = 13.3, 95% CI = 1.7 - 103.6). Mean APOE concentrations were lower in AD patients; the lowest levels were observed in male patients carrying PP and/or XX genotypes ( p = 0.006) and in patients carrying PP and/or XX genotypes together with the e* 4 allele ( p = 0.003). In AD women, ESR1 PP and XX genotypes were also associated with lower MMSE values ( p = 0.0007). Conclusion: The present data suggest that the involvement of ESR1 polymorphisms in AD onset is mediated by the regulation of apoE expression. ESR1 polymorphisms are also associated with a faster cognitive decline in the women AD patients. Copyright (C) 2006 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据